08 May 2025
Xbrane Biopharma releases Interim Report January-March 2025
05 May 2025
Announcement from the annual general meeting in Xbrane Biopharma AB
04 May 2025
Invitation to presentation of Xbrane Biopharma’s interim report January – March 2025 on May 8, 2025
14 Apr 2025
Announcement from extra general meeting in Xbrane Biopharma AB
02 Apr 2025
NOTICE OF ANNUAL GENERAL MEETING IN XBRANE BIOPHARMA AB
31 Mar 2025
XBRANE BIOPHARMA RELEASES ANNUAL AND SUSTAINABILITY REPORT FOR 2024
20 Mar 2025
Notice of Extra General Meeting in Xbrane Biopharma AB
20 Mar 2025
Xbrane has entered into an agreement to sell XB003 (Cimzia biosimilar candidate) and parts of its organization to Alvotech for a total consideration of SEK 275 million
20 Feb 2025
Xbrane Biopharma releases Year-end Report 2024
17 Feb 2025
Invitation to presentation of Xbrane Biopharma’s Year-end report 2024 on February 20, 2025
31 Jan 2025
The number of shares and votes in Xbrane has changed as a result of 2,706,898 shares being issued during January through the exercise of warrants in December 2024.
09 Jan 2025
Xbrane Biopharma AB (publ) (“Xbrane” or “the company) appoints Jane Benyamin as acting Chief Financial Officer.
31 Dec 2024
XBRANE RE-SUBMITS BLA FOR RANIBIZUMAB BIOSIMILAR CANDIDATE TO FDA
18 Dec 2024
Xbrane announces outcome of exercise of warrants of series TO1
02 Dec 2024
XBRANE BIOPHARMA’S PRINCIPAL OWNER SYSTEMATIC GROUP PROVIDES A SHORT-TERM LOAN OF SEK 20 M TO THE COMPANY